Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	390.73M -44.2%
Revenue (ttm)	88.38M +92.8%
Net Income	-88.60M
EPS	-3.84
Shares Out	23.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,389
Open	17.00
Previous Close	17.08
Day's Range	16.84 - 17.00
52-Week Range	13.64 - 31.90
Beta	0.37
Analysts	Buy
Price Target	33.62 (+98.94%)
Earnings Date	Sep 17, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for RVU stock is "Buy." The 12-month stock price target is zł 33.62, which is an increase of 98.94% from the latest price.

Price Target

zł 33.62

(98.94% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 14, 2026

Data Sources Report a data error